Clinical Trial Search

Primary: Incidence of Clinical Episodes of Malaria — 338.1; 421.3; 178.9 Episodes per 1,000 child years at risk

Primary: Timeline Follow Back (TLFB) — -0.82; -0.71 drinks per drinking day

Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33

Primary: Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall — 69; 341 Participants

Primary: To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. — -6.29; -2.60 score on a scale

Primary: Post Operative Pain — 13; 10 Participants

Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Main Study — 30; 26; 0; 1 Participants

Primary: Percent Change From Baseline in LDL-C — -60.0; -7.0 percent change in LDL-C — p=<0.001

Primary: Progression Free Survival (PFS) Based on Investigator Assessment — 106.9; 15.0 months — p=< 0.0001

Primary: Number of Participants With Local and Systemic Solicited Treatment Emergent Adverse Events (TEAEs) in Primary Vaccination Cohort (PVC):- AZD2816 (4), Booster…

Primary: Seroresponse — 253; 250 Participants

Primary: Shift From Baseline in Distortion Product Otoacoustic Emission at TOC Visit — 2; 1; 0; 0 Participants

Primary: Rate of Clinically Significant Exacerbations of Asthma — 0.45; 1.31 Exacerbations per year — p=<0.001

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation, and TEAEs of Special Interest. — 8; 3; 2; 7…

Primary: Percentage of Numerical Rating Scale (NRS) Responders at Day 5 — 72.5; 49.4 percentage of participants — p=0.002